Cancer incidence and therapies have surged, but clinical trial recruitment remains a major bottleneck. Complex protocols and overburdened investigators contribute to under-recruitment, delaying treatments and increasing costs. The ISL role within Medical Affairs supports investigators scientifically, improving recruitment, protocol comprehension, and trial success.
Surveying 100 KOLs (mostly oncology) revealed dissatisfaction with traditional face-to-face advisory boards: unclear goals, minimal follow-up, and patient risk during physician absence. All respondents preferred virtual advisory boards, believing online interaction maintains quality and reduces patient impact. Digital platforms are safer and more efficient for Medical Affairs.
Patient enrolment is a major challenge, with 90% of U.S. trials failing recruitment targets and early termination in 19% of studies. Investigator Science Liaisons (ISLs) provide scientific support, clarify complex protocols, and improve Sponsor–investigator interaction. Trials using ISLs saw 50% higher recruitment and over 70% investigator satisfaction.
Digital advisory boards reduce travel, fatigue, and time away from patients for doctors and KOLs, while enabling global, multi-day discussions. MphaR’s platform improves engagement, simplifies navigation, maximizes efficiency, and cuts costs, supporting knowledge sharing, practical solutions, and better patient care.
Under-recruitment jeopardizes trials, costs $600K–$8M/day, delays drug launches, and denies patients experimental treatments. ISLs, a new Medical Affairs role, support investigators early, clarify protocols, solve site issues, and maintain engagement—boosting recruitment, strengthening relationships, and bridging R&D with real-world practice.
Thank you! Your message has been sent.
